Cargando…

Pembrolizumab-induced myocarditis in a patient with malignant mesothelioma: plasma exchange as a successful emerging therapy—case report

Malignant mesothelioma is an aggressive cancer associated with prior exposure to asbestos and dismal prognosis. Immune checkpoint inhibitor therapy is currently approved by the Food and Drug Administration for pre-treated malignant pleural mesothelioma. We describe a 75-year-old patient with dissemi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schiopu, Sanziana R. I., Käsmann, Lukas, Schönermarck, Ulf, Fischereder, Michael, Grabmaier, Ulrich, Manapov, Farkhad, Rauch, Josefine, Orban, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947381/ https://www.ncbi.nlm.nih.gov/pubmed/33718042 http://dx.doi.org/10.21037/tlcr-20-1095

Ejemplares similares

Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy
por: Käsmann, Lukas, et al.
Publicado: (2020)

Erratum to pembrolizumab-induced myocarditis in a patient with malignant mesothelioma: plasma exchange as a successful emerging therapy—case report
Publicado: (2021)

Membrane and centrifugal therapeutic plasma exchange: practical difficulties in anticoagulating the extracorporeal circuit
por: Seibt, Tobias, et al.
Publicado: (2014)

Chemo-/immuno-/radiotherapy combination in treatment of solid cancer
por: Käsmann, Lukas, et al.
Publicado: (2019)

NICOLAS, DETERRED and KEYNOTE 799: focus on escalation of conventionally fractionated chemoradiotherapy by immune checkpoint inhibition in unresectable stage III non-small cell lung cancer
por: Manapov, Farkhad, et al.
Publicado: (2022)

In regards to Chu et al.: Patterns of brain metastasis immediately before prophylactic cranial irradiation (PCI): implications for PCI optimization in limited-stage small cell lung cancer
por: Käsmann, Lukas, et al.
Publicado: (2020)

Positron Emission Tomography/Computed Tomography (PET/CT)-Based, Local Consolidative Radiotherapy after Chemoimmunotherapy in Metastatic, Non-Oncogene-Addicted Non-Small-Cell Lung Cancer (NSCLC)
por: Angelini, Lucia, et al.
Publicado: (2023)

PD-L1 expression on tumor cells as a potential predictive biomarker for patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab
por: Käsmann, Lukas, et al.
Publicado: (2023)

Case report: de novo ANCA-associated vasculitis after kidney transplantation treated with rituximab and plasma exchange
por: Sagmeister, Michael S., et al.
Publicado: (2018)

Implementation of durvalumab maintenance treatment after concurrent chemoradiotherapy in inoperable stage III non-small cell lung cancer (NSCLC)—a German radiation oncology survey
por: Käsmann, Lukas, et al.
Publicado: (2020)

Timing of tumor-induced atelectasis resolution and pulmonary function restoration in the course of image-guided moderate hypofractionated thoracic irradiation: a case report and mini-review of literature
por: Bodensohn, Raphael, et al.
Publicado: (2021)

Radiation-Induced Lung Injury: Prevention, Diagnostics and Therapy in the Era of the COVID-19 Pandemic
por: Käsmann, Lukas, et al.
Publicado: (2022)

Exceptional Regression of Malignant Pleural Mesothelioma with Pembrolizumab Monotherapy
por: Hearon, Bernard F., et al.
Publicado: (2020)

Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma
por: Bickel, Angelika, et al.
Publicado: (2016)

Humoral immunity to SARS-CoV-2 vaccination in haemodialysis patients: (Response to: Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine.)
por: Hasmann, Sandra, et al.
Publicado: (2021)

Clinical Management and Outcome of Grade III Pneumonitis after Chemoradioimmunotherapy for Inoperable Stage III Non-Small Cell Lung Cancer—A Prospective Longitudinal Assessment
por: Kauffmann-Guerrero, Diego, et al.
Publicado: (2021)

Cyclosporine as a preferred calcineurin inhibitor in renal allograft recipients with COVID-19 infection
por: Kemmner, Stephan, et al.
Publicado: (2020)

Periodic repolarization dynamics in a patient with subacute myocarditis
por: Schüttler, Dominik, et al.
Publicado: (2021)

Prophylactic cranial irradiation in small-cell lung cancer: update on patient selection, efficacy and outcomes
por: Manapov, Farkhad, et al.
Publicado: (2018)

Association of Planning Target Volume with Patient Outcome in Inoperable Stage III NSCLC Treated with Chemoradiotherapy: A Comprehensive Single-Center Analysis
por: Karin, Monika, et al.
Publicado: (2020)

Durvalumab after Chemoradiotherapy for PD-L1 Expressing Inoperable Stage III NSCLC Leads to Significant Improvement of Local-Regional Control and Overall Survival in the Real-World Setting
por: Taugner, Julian, et al.
Publicado: (2021)

Radiation Induced Abscopal Effect in a Patient With Malignant Pleural Mesothelioma on Pembrolizumab
por: Rittberg, Rebekah, et al.
Publicado: (2022)

Initial report on feasibility of PET/CT-based image-guided moderate hypofractionated thoracic irradiation in node-positive non-small cell lung Cancer patients with poor prognostic factors and strongly diminished lung function: a retrospective analysis
por: Eze, Chukwuka, et al.
Publicado: (2019)

Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients
por: Taugner, Julian, et al.
Publicado: (2021)

Pembrolizumab-Associated CD8(+) Vasculitic Mononeuritis Multiplex in a Patient With Mesothelioma
por: Baldauf, Michaela C., et al.
Publicado: (2021)

Retrospective Evaluation of the Use of Pembrolizumab in Malignant Mesothelioma in a Real-World Australian Population
por: Ahmadzada, Tamkin, et al.
Publicado: (2020)

Abscopal effect in a patient with malignant pleural mesothelioma treated with palliative radiotherapy and pembrolizumab
por: Mampuya, Wambaka Ange, et al.
Publicado: (2021)

Drug-induced CYP induction as therapy for tacrolimus intoxication
por: Hoppe, John M., et al.
Publicado: (2022)

Pembrolizumab-Induced Myocarditis and Delayed Acute Inflammatory Demyelinating Polyradiculoneuropathy
por: Dalal, Fazal, et al.
Publicado: (2022)

Case report: Electrocardiographic changes in pembrolizumab-induced fatal myocarditis
por: Nishiyama, Kazuhiro, et al.
Publicado: (2023)

Pattern-of-failure and salvage treatment analysis after chemoradiotherapy for inoperable stage III non-small cell lung cancer
por: Taugner, Julian, et al.
Publicado: (2020)

Blocking LFA-1 Aggravates Cardiac Inflammation in Experimental Autoimmune Myocarditis
por: Weckbach, Ludwig T., et al.
Publicado: (2019)

Treatment patterns and prognosis of patients with inoperable stage III NSCLC after completion of concurrent chemoradiotherapy ± immune checkpoint inhibition: a decade-long single-center historical analysis
por: Flörsch, Benedikt, et al.
Publicado: (2022)

Rapid Response to the Combination of Lenvatinib and Pembrolizumab in Patients with Advanced Carcinomas (Lung Adenocarcinoma and Malignant Pleural Mesothelioma)
por: Shalata, Walid, et al.
Publicado: (2021)

Hypofractionated Radiotherapy for Anaplastic Thyroid Cancer: Systematic Review and Pooled Analysis
por: Oliinyk, Dmytro, et al.
Publicado: (2020)

Clinical Outcome and Toxicity in the Treatment of Anaplastic Thyroid Cancer in Elderly Patients
por: Augustin, Teresa, et al.
Publicado: (2020)

Role of surgery to the primary tumor in metastatic anaplastic thyroid carcinoma: pooled analysis and SEER-based study
por: Oliinyk, Dmytro, et al.
Publicado: (2022)

Effect of Apheresis for ABO and HLA Desensitization on Anti-Measles Antibody Titers in Renal Transplantation
por: Schönermarck, Ulf, et al.
Publicado: (2011)

Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab
por: Minchom, Anna, et al.
Publicado: (2020)

Maximum standardized uptake value of primary tumor (SUVmax_PT) and horizontal range between two most distant PET-positive lymph nodes predict patient outcome in inoperable stage III NSCLC patients after chemoradiotherapy
por: Roengvoraphoj, Olarn, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5qqkrlf3cdlkehgr7kdj1u3j1o